ECSP14013217A - 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk. - Google Patents
4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.Info
- Publication number
- ECSP14013217A ECSP14013217A ECSP14013217A ECSP14013217A EC SP14013217 A ECSP14013217 A EC SP14013217A EC SP14013217 A ECSP14013217 A EC SP14013217A EC SP14013217 A ECSP14013217 A EC SP14013217A
- Authority
- EC
- Ecuador
- Prior art keywords
- benzamidas
- imidazotriazin
- imidazopiridazin
- formula
- btk inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente invención se refiere a compuestos de anillos de piridina fusionados de 5-6 miembros según la fórmula I Fórmula Io una sal farmacéuticamente aceptable de los mismos o a composiciones farmacéuticas que comprenden estos compuestos y a su uso en terapia. En particular, la presente invención se refiere al uso de compuestos de anillos de piridina fusionados de 5-6 miembros según la fórmula I en el tratamiento de trastornos mediados por tirosina cinasa de Bruton (Btk).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161509397P | 2011-07-19 | 2011-07-19 | |
EP11174578 | 2011-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP14013217A true ECSP14013217A (es) | 2015-03-31 |
Family
ID=47557677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP14013217 ECSP14013217A (es) | 2011-07-19 | 2014-02-19 | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk. |
Country Status (35)
Country | Link |
---|---|
US (7) | US9290504B2 (es) |
EP (4) | EP4249076A3 (es) |
JP (6) | JP5826931B2 (es) |
KR (2) | KR101802689B1 (es) |
CN (2) | CN106243113B (es) |
AU (4) | AU2012285987C1 (es) |
BR (1) | BR112014001255B1 (es) |
CA (1) | CA2841886C (es) |
CL (1) | CL2014000130A1 (es) |
CO (1) | CO6940411A2 (es) |
CR (1) | CR20140030A (es) |
DK (2) | DK3689878T3 (es) |
DO (1) | DOP2014000008A (es) |
EA (2) | EA037644B1 (es) |
EC (1) | ECSP14013217A (es) |
ES (3) | ES2708224T3 (es) |
GT (1) | GT201400009A (es) |
HR (2) | HRP20212021T1 (es) |
HU (3) | HUE056249T2 (es) |
IL (3) | IL230511B (es) |
IN (1) | IN2014CN00408A (es) |
LT (1) | LT2734522T (es) |
MA (1) | MA35348B1 (es) |
MX (1) | MX342983B (es) |
MY (1) | MY192354A (es) |
PE (1) | PE20141681A1 (es) |
PH (1) | PH12017500166A1 (es) |
PL (2) | PL3689878T3 (es) |
PT (1) | PT3689878T (es) |
RS (2) | RS58177B1 (es) |
SG (1) | SG10201605913VA (es) |
SI (2) | SI2734522T1 (es) |
TN (1) | TN2014000027A1 (es) |
UA (1) | UA115312C2 (es) |
WO (1) | WO2013010868A1 (es) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120101113A1 (en) * | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
CA2800913C (en) | 2010-06-03 | 2019-07-23 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
WO2012158764A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
US9138436B2 (en) | 2011-07-13 | 2015-09-22 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
CA2841886C (en) * | 2011-07-19 | 2016-08-16 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
MX361815B (es) | 2012-09-10 | 2018-12-17 | Principia Biopharma Inc | Compuestos pirazolopirimidinicos como inhibidores de cinasas. |
RU2015115631A (ru) | 2012-09-26 | 2016-11-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Модулирование ire1 |
WO2014055934A2 (en) * | 2012-10-04 | 2014-04-10 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
WO2014113942A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
TW201441234A (zh) | 2013-01-23 | 2014-11-01 | Merck Sharp & Dohme | Btk抑制劑 |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
SG11201509842SA (en) | 2013-05-30 | 2015-12-30 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
ES2706150T3 (es) * | 2013-07-31 | 2019-03-27 | Merck Patent Gmbh | Piridinas, pirimidinas y pirazinas, como inhibidores de BTK y sus usos |
WO2015057992A1 (en) * | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
CN105979948A (zh) | 2013-12-05 | 2016-09-28 | 安塞塔制药公司 | Pi3k抑制剂和btk抑制剂的治疗组合 |
WO2015095102A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
EP3082809B1 (en) | 2013-12-20 | 2021-01-20 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
WO2015110923A2 (en) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
SG11201606858RA (en) | 2014-02-21 | 2016-09-29 | Principia Biopharma Inc | Salts and solid form of a btk inhibitor |
WO2015185998A2 (en) | 2014-04-11 | 2015-12-10 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase |
US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
US9949971B2 (en) | 2014-06-17 | 2018-04-24 | Acerta Pharma B.V. | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor |
CN106999494A (zh) * | 2014-08-01 | 2017-08-01 | 药品循环有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
WO2016020901A1 (en) | 2014-08-07 | 2016-02-11 | Acerta Pharma B.V. | Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate |
TW201609099A (zh) | 2014-08-11 | 2016-03-16 | 艾森塔製藥公司 | 使用布魯頓(Bruton)氏酪胺酸激酶(BTK)抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法 |
AR101504A1 (es) * | 2014-08-11 | 2016-12-21 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 |
EP3179991B1 (en) * | 2014-08-11 | 2021-10-06 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
US20170231995A1 (en) | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment |
HRP20220738T1 (hr) | 2014-08-11 | 2022-08-19 | Acerta Pharma B.V. | Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1 |
RU2658821C1 (ru) | 2014-08-18 | 2018-06-25 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соль моноциклического производного пиридина и ее кристалл |
EP3191098A4 (en) * | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2016055982A1 (en) * | 2014-10-10 | 2016-04-14 | Acerta Pharma B.V. | Quinoline and quinazoline compounds |
WO2016087994A1 (en) | 2014-12-05 | 2016-06-09 | Acerta Pharma B.V. | Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment |
MX2017007973A (es) * | 2014-12-18 | 2018-02-09 | Principia Biopharma Inc | Tratamiento de penfigo. |
WO2016106624A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Tertiary alcohol imidazopyrazine btk inhibitors |
WO2016106629A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106627A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106623A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
WO2016106626A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors |
WO2016106625A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016128912A1 (en) * | 2015-02-12 | 2016-08-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor |
WO2016161571A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Indazole and azaindazole btk inhibitors |
WO2016192074A1 (en) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016210165A1 (en) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
LT3317281T (lt) * | 2015-07-02 | 2020-07-27 | Acerta Pharma B.V. | (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamido kompozicijų kietosios formos |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
US20190022092A1 (en) | 2015-09-15 | 2019-01-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist |
WO2017077507A1 (en) | 2015-11-06 | 2017-05-11 | Acerta Pharma B.V. | Imidazopyrazine inhibitors of bruton's tyrosine kinase |
EP3402503B1 (en) | 2016-01-13 | 2020-10-21 | Acerta Pharma B.V. | Therapeutic combinations of an antifolate and a btk inhibitor |
IL263815B (en) | 2016-06-29 | 2022-07-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile |
WO2018002958A1 (en) * | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
CA3032795C (en) * | 2016-06-30 | 2021-06-22 | Yubin LV | Imidazopyridinamine phenyl derivative and use thereof |
EP3492471B1 (en) * | 2016-08-17 | 2020-12-02 | Shenzhen TargetRx, Inc. | Fused bicyclic compound for inhibiting activity of tyrosine kinase |
WO2018064797A1 (zh) * | 2016-10-05 | 2018-04-12 | 杭州领业医药科技有限公司 | Acp-196的晶型及其制备方法和药物组合物 |
CN107056786B (zh) * | 2016-10-14 | 2019-05-07 | 苏州明锐医药科技有限公司 | 阿卡替尼的制备方法 |
CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
MX2019007156A (es) * | 2016-12-21 | 2019-09-05 | Acerta Pharma Bv | Inhibidores de imidazopirazina de la tirosina cinasa de bruton. |
WO2018115965A1 (en) | 2016-12-23 | 2018-06-28 | Acerta Pharma Bv | Solid forms of imidazopyrazine compounds |
CN106588937B (zh) | 2017-01-16 | 2018-09-21 | 东莞市真兴贝特医药技术有限公司 | 咪唑并吡嗪类化合物及其制备方法和应用 |
WO2018134786A1 (en) | 2017-01-19 | 2018-07-26 | Acerta Pharma B.V. | Compositions and methods for the assessment of drug target occupancy for bruton's tyrosine kinase |
CN106831787B (zh) | 2017-01-20 | 2018-10-23 | 成都倍特药业有限公司 | 用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用 |
US10899770B2 (en) | 2017-02-20 | 2021-01-26 | Hangzhou Solipharma Co., Ltd. | Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof |
JP2020508326A (ja) | 2017-02-24 | 2020-03-19 | ギリアド サイエンシズ, インコーポレイテッド | ブルトン型チロシンキナーゼの阻害剤 |
EP3585788A1 (en) | 2017-02-24 | 2020-01-01 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
KR102627756B1 (ko) * | 2017-03-22 | 2024-01-23 | 쑤저우 바이지부공 파마수티컬 테크널러지 컴퍼니 리미티드 | 브루톤 타이로신 키나제 억제제 |
JOP20190233A1 (ar) | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
US10800787B2 (en) | 2017-04-20 | 2020-10-13 | Apotex Inc. | Process for the preparation of acalabrutinib |
US10717740B2 (en) | 2017-06-13 | 2020-07-21 | Dr. Reddy's Laboratories Limited. | Solid forms of acalabrutinib and process for preparation thereof |
CN107522701B (zh) * | 2017-09-01 | 2019-11-08 | 苏州富士莱医药股份有限公司 | 一种治疗慢性淋巴细胞白血病的BTK抑制剂Acalabrutinib的合成方法 |
CN107602564B (zh) * | 2017-09-20 | 2019-08-30 | 南京亘泰医药技术有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
AU2018335617B2 (en) | 2017-09-25 | 2021-12-09 | Astrazeneca Ab | Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer |
US11161851B2 (en) | 2017-11-06 | 2021-11-02 | Suzhou Pengxu Pharmatech Co. Ltd. | Processes to produce acalabrutinib |
CN109836416B (zh) * | 2017-11-27 | 2023-02-03 | 苏州鹏旭医药科技有限公司 | 一种化合物的制备方法 |
CA3087474A1 (en) * | 2018-01-05 | 2019-07-11 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline forms of acalabrutinib, processes for preparation and use thereof |
CN108250186B (zh) * | 2018-02-07 | 2020-01-14 | 杭州科巢生物科技有限公司 | Acalabrutinib及其中间体的合成方法 |
CN110256438B (zh) * | 2018-03-12 | 2020-07-17 | 新发药业有限公司 | 一种阿可替尼的制备方法 |
EP3777860A4 (en) | 2018-03-28 | 2021-12-15 | Eisai R&D Management Co., Ltd. | THERAPEUTIC FOR HEPATOCELLULAR CARCINOMA |
EP3789040A4 (en) | 2018-04-27 | 2022-03-09 | ONO Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT |
TW202014184A (zh) | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
WO2019239374A1 (en) | 2018-06-13 | 2019-12-19 | Acerta Pharma B.V. | Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase |
CA3104470A1 (en) | 2018-06-19 | 2019-12-26 | Regeneron Pharmaceuticals, Inc. | Anti-factor xii/xiia antibodies and uses thereof |
EP3587421A1 (en) | 2018-06-29 | 2020-01-01 | Sandoz AG | Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide |
US20220127270A1 (en) * | 2018-08-29 | 2022-04-28 | Acerta Pharma B.V. | PROCESSES FOR THE PREPARATION OF 4-{8-AMINO-3-[(2S)-1-(BUT-2-YNOYL)-PYRROLIDIN-2-YL]IMIDAZO[1,5-a]-PYRAZIN-1-YL}N-(PYRIDIN-2-YL)-BENZAMIDE |
WO2020053795A2 (en) | 2018-09-13 | 2020-03-19 | Fresenius Kabi Oncology Ltd. | Process for the preparation of acalabrutinib and its intermediates |
WO2020065667A1 (en) | 2018-09-25 | 2020-04-02 | Cipla Limited | Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor |
CN109020977B (zh) * | 2018-10-26 | 2020-11-13 | 安庆奇创药业有限公司 | 一种Acalabrutinib的制备方法 |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
CN111377928A (zh) * | 2018-12-28 | 2020-07-07 | 南京艾德凯腾生物医药有限责任公司 | 一种制备Acalabrutinib的方法 |
CN111377929A (zh) * | 2018-12-28 | 2020-07-07 | 南京艾德凯腾生物医药有限责任公司 | 一种可用于治疗白血病阿卡替尼(Acalabrutinib)制备的方法 |
EP3930712A4 (en) * | 2019-02-27 | 2022-09-28 | Optikira LLC | IMIDAZOLOPYRAZINE COMPOUNDS FOR IRE1 INHIBITION |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US20220153744A1 (en) | 2019-03-27 | 2022-05-19 | Assia Chemical Industries Ltd. | Solid state forms of acalabrutinib |
WO2020225831A1 (en) * | 2019-05-09 | 2020-11-12 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide |
WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
CN110563733A (zh) * | 2019-09-12 | 2019-12-13 | 安帝康(无锡)生物科技有限公司 | 作为选择性btk抑制剂的咪唑并吡嗪类化合物 |
MX2022005250A (es) | 2019-11-04 | 2022-06-08 | Astrazeneca Ab | Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b. |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
PE20230992A1 (es) | 2020-06-19 | 2023-06-23 | Acerta Pharma Bv | Formas farmaceuticas de maleato de acalabrutinib |
CN112386597B (zh) * | 2020-10-15 | 2022-03-15 | 天津济坤医药科技有限公司 | 泽布替尼在制备治疗肺纤维化疾病药物中的应用 |
CN113264938B (zh) * | 2021-07-21 | 2021-11-02 | 北京鑫开元医药科技有限公司 | 一种咪唑并[1,5-a]吡嗪-8-胺类化合物、制备方法、药物组合物和应用 |
WO2023014817A1 (en) | 2021-08-03 | 2023-02-09 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002526500A (ja) | 1998-09-18 | 2002-08-20 | ビーエーエスエフ アクチェンゲゼルシャフト | プロテインキナーゼ阻害剤としてのピロロピリミジン |
CN1390220A (zh) | 1999-09-17 | 2003-01-08 | 艾博特股份有限两合公司 | 作为治疗剂的激酶抑制剂 |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
CA2542481A1 (en) | 2003-10-15 | 2005-04-28 | Osi Pharmaceuticals, Inc. | Imidazopyrazine tyrosine kinase inhibitors |
US7534797B2 (en) | 2004-04-02 | 2009-05-19 | Osi Pharmaceuticals, Inc. | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors |
WO2007061737A2 (en) | 2005-11-17 | 2007-05-31 | Osi Pharmaceuticals, Inc. | FUSED BICYCLIC mTOR INHIBITORS |
AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
US7651687B2 (en) | 2006-03-13 | 2010-01-26 | Osi Pharmaceuticals, Inc. | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors |
ATE531263T1 (de) | 2006-09-22 | 2011-11-15 | Pharmacyclics Inc | Hemmer der bruton-tyrosinkinase |
EP2139487B1 (en) * | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
US20120101113A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
BRPI0821660A2 (pt) | 2007-12-13 | 2015-06-16 | Novartis Ag | Combinações de agentes terapêuticos para tratamento de câncer |
CA2721060A1 (en) * | 2008-04-09 | 2009-10-15 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
US9095592B2 (en) | 2008-11-07 | 2015-08-04 | The Research Foundation For The State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
US8765754B2 (en) * | 2009-04-29 | 2014-07-01 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
BR112012019765B1 (pt) * | 2010-02-08 | 2021-08-31 | Merck Sharp & Dohme B.V | Composto, e, uso de um composto |
UY33288A (es) | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
KR101537148B1 (ko) | 2010-05-31 | 2015-07-15 | 오노 야꾸힝 고교 가부시키가이샤 | 푸리논 유도체 |
CA2800913C (en) | 2010-06-03 | 2019-07-23 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
US20120053189A1 (en) | 2010-06-28 | 2012-03-01 | Pharmacyclics, Inc. | Btk inhibitors for the treatment of immune mediated conditions |
KR102052670B1 (ko) | 2011-05-17 | 2019-12-06 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키나아제 저해제 |
EP2726077A4 (en) | 2011-06-28 | 2014-12-10 | Pharmacyclics Inc | METHODS AND COMPOSITIONS FOR INHIBITING BONE RESORPTION |
US9138436B2 (en) | 2011-07-13 | 2015-09-22 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
EP2734523A1 (en) | 2011-07-19 | 2014-05-28 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors |
CA2841886C (en) * | 2011-07-19 | 2016-08-16 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
KR102258778B1 (ko) | 2011-10-19 | 2021-06-02 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(btk)의 억제제의 용도 |
US20140212425A1 (en) | 2011-12-05 | 2014-07-31 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
TW201441234A (zh) | 2013-01-23 | 2014-11-01 | Merck Sharp & Dohme | Btk抑制劑 |
EA201591718A1 (ru) | 2013-03-14 | 2016-05-31 | Фармасайкликс Элэлси | Комбинации ингибиторов тирозинкиназы брутона и ингибиторов cyp3a4 |
WO2014143807A2 (en) | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
JP6575952B2 (ja) | 2013-04-08 | 2019-09-18 | ファーマサイクリックス エルエルシー | イブルチニブ併用療法 |
WO2015018522A1 (en) | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
-
2012
- 2012-07-11 CA CA2841886A patent/CA2841886C/en active Active
- 2012-07-11 KR KR1020167026989A patent/KR101802689B1/ko active IP Right Grant
- 2012-07-11 PL PL19215783T patent/PL3689878T3/pl unknown
- 2012-07-11 MY MYPI2014000148A patent/MY192354A/en unknown
- 2012-07-11 BR BR112014001255-5A patent/BR112014001255B1/pt active IP Right Grant
- 2012-07-11 EP EP23168571.0A patent/EP4249076A3/en active Pending
- 2012-07-11 SG SG10201605913VA patent/SG10201605913VA/en unknown
- 2012-07-11 PL PL12733505T patent/PL2734522T3/pl unknown
- 2012-07-11 WO PCT/EP2012/063552 patent/WO2013010868A1/en active Application Filing
- 2012-07-11 RS RS20190018A patent/RS58177B1/sr unknown
- 2012-07-11 HR HRP20212021TT patent/HRP20212021T1/hr unknown
- 2012-07-11 EA EA201992270A patent/EA037644B1/ru unknown
- 2012-07-11 DK DK19215783.2T patent/DK3689878T3/da active
- 2012-07-11 EP EP18203086.6A patent/EP3495368B1/en active Active
- 2012-07-11 ES ES12733505T patent/ES2708224T3/es active Active
- 2012-07-11 CN CN201610692460.4A patent/CN106243113B/zh active Active
- 2012-07-11 CN CN201280045383.3A patent/CN103889987B/zh active Active
- 2012-07-11 AU AU2012285987A patent/AU2012285987C1/en active Active
- 2012-07-11 PE PE2014000096A patent/PE20141681A1/es active IP Right Grant
- 2012-07-11 EP EP12733505.7A patent/EP2734522B1/en active Active
- 2012-07-11 ES ES19215783T patent/ES2904707T3/es active Active
- 2012-07-11 UA UAA201401626A patent/UA115312C2/uk unknown
- 2012-07-11 IN IN408CHN2014 patent/IN2014CN00408A/en unknown
- 2012-07-11 DK DK12733505.7T patent/DK2734522T3/en active
- 2012-07-11 EA EA201490300A patent/EA034558B1/ru active Protection Beyond IP Right Term
- 2012-07-11 EP EP19215783.2A patent/EP3689878B1/en active Active
- 2012-07-11 MX MX2014000746A patent/MX342983B/es active IP Right Grant
- 2012-07-11 RS RS20211594A patent/RS62760B1/sr unknown
- 2012-07-11 KR KR1020147003955A patent/KR101702727B1/ko active Protection Beyond IP Right Term
- 2012-07-11 SI SI201231495T patent/SI2734522T1/sl unknown
- 2012-07-11 HU HUE19215783A patent/HUE056249T2/hu unknown
- 2012-07-11 ES ES18203086T patent/ES2950569T3/es active Active
- 2012-07-11 HU HUE12733505A patent/HUE041987T2/hu unknown
- 2012-07-11 LT LTEP12733505.7T patent/LT2734522T/lt unknown
- 2012-07-11 PT PT192157832T patent/PT3689878T/pt unknown
- 2012-07-11 US US14/233,418 patent/US9290504B2/en active Active
- 2012-07-11 SI SI201231956T patent/SI3689878T1/sl unknown
- 2012-07-11 JP JP2014520606A patent/JP5826931B2/ja active Active
-
2014
- 2014-01-16 IL IL230511A patent/IL230511B/en active IP Right Grant
- 2014-01-17 GT GT201400009A patent/GT201400009A/es unknown
- 2014-01-17 CO CO14008868A patent/CO6940411A2/es unknown
- 2014-01-17 CL CL2014000130A patent/CL2014000130A1/es unknown
- 2014-01-17 DO DO2014000008A patent/DOP2014000008A/es unknown
- 2014-01-20 TN TNP2014000027A patent/TN2014000027A1/en unknown
- 2014-01-20 CR CR20140030A patent/CR20140030A/es unknown
- 2014-02-12 MA MA36752A patent/MA35348B1/fr unknown
- 2014-02-19 EC ECSP14013217 patent/ECSP14013217A/es unknown
-
2015
- 2015-10-14 JP JP2015202737A patent/JP6251220B2/ja active Active
-
2016
- 2016-02-09 US US15/019,561 patent/US9790226B2/en active Active
- 2016-02-09 US US15/019,543 patent/US9758524B2/en active Active
- 2016-06-09 AU AU2016203837A patent/AU2016203837B2/en active Active
-
2017
- 2017-01-27 PH PH12017500166A patent/PH12017500166A1/en unknown
- 2017-08-03 US US15/668,385 patent/US10239883B2/en active Active
- 2017-10-12 JP JP2017198591A patent/JP6617130B2/ja active Active
- 2017-12-22 AU AU2017279778A patent/AU2017279778B2/en active Active
-
2019
- 2019-01-21 HR HRP20190135TT patent/HRP20190135T1/hr unknown
- 2019-02-14 US US16/276,161 patent/US10934296B2/en active Active
- 2019-03-15 JP JP2019047900A patent/JP6749444B2/ja active Active
- 2019-05-26 IL IL266894A patent/IL266894B/en unknown
- 2019-12-04 AU AU2019275591A patent/AU2019275591B2/en active Active
-
2020
- 2020-08-11 JP JP2020135694A patent/JP7054721B2/ja active Active
-
2021
- 2021-01-05 US US17/142,202 patent/US20210230166A1/en not_active Abandoned
- 2021-04-14 HU HUS2100012C patent/HUS2100012I1/hu unknown
-
2022
- 2022-03-18 IL IL291489A patent/IL291489A/en unknown
- 2022-04-04 JP JP2022062400A patent/JP2022088618A/ja not_active Withdrawn
- 2022-11-10 US US17/984,242 patent/US20230331729A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP14013217A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk. | |
CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
EA201590343A1 (ru) | Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
EA201590053A1 (ru) | Модуляторы пути системы комплемента и их применение | |
CO6660497A2 (es) | Derivados del ácido nft-2-ilacético para tratar el sida | |
EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
UA109010C2 (en) | MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY | |
EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
EA201591195A1 (ru) | Новые хинолоновые производные | |
ECSP13013011A (es) | Triazolopiridinas | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
BR112013000059A2 (pt) | derivados de piperidina e seus usos para o tratamento de distúrbios metabólicos | |
ECSP14013275A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
AR092247A1 (es) | INHIBIDORES DE LA b-SECRETASA | |
BR112014004447A2 (pt) | bifenilcarboxamidas como inibidores de quinase rock | |
EA201490573A1 (ru) | Соединение бензотиазолона | |
UY33806A (es) | ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7? | |
NI201400004A (es) | 4 - imidazopiridazin - 1 - il - benzamidas y 4 - imidazotriazin - 1 - il - benzamidas como inhibidores de btk | |
GT201500189A (es) | Inhibidores de autotaxina | |
CU20100004A7 (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
CU20100003A7 (es) | Derivados trisustituídas de pirimidina para el tratamiento de enfermedades proliferativas | |
UA111851C2 (uk) | Сполуки піридазинону та їх використання як інгібіторів daao | |
CU20100005A7 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas |